A derivation of the IS performed in initial diagnostic biopsies (ISB) before nCRT has the advantage of evaluating the effect of the initial immune infiltrate (i.e., CD3+ and CD8+ T cells in the tumor) on both response to nCRT and clinical outcome (Figure 1). The gene discussed is CD8A; the disease is neoplasm.